Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study
- Supplementary File 1:
PDF-Document (PDF, 736 KiB)
Tkachuk, A.P.; Bykonia, E.N.; Popova, L.I.; Kleymenov, D.A.; Semashko, M.A.; Chulanov, V.P.; Fitilev, S.B.; Maksimov, S.L.; Smolyarchuk, E.A.; Manuylov, V.A.; Vasina, D.V.; Gushchin, V.A.; Gintsburg, A.L. Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study. Vaccines 2020, 8, 652. https://doi.org/10.3390/vaccines8040652
Tkachuk AP, Bykonia EN, Popova LI, Kleymenov DA, Semashko MA, Chulanov VP, Fitilev SB, Maksimov SL, Smolyarchuk EA, Manuylov VA, Vasina DV, Gushchin VA, Gintsburg AL. Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study. Vaccines. 2020; 8(4):652. https://doi.org/10.3390/vaccines8040652
Chicago/Turabian StyleTkachuk, Artem P., Evgeniia N. Bykonia, Liubov I. Popova, Denis A. Kleymenov, Maria A. Semashko, Vladimir P. Chulanov, Sergey B. Fitilev, Semyon L. Maksimov, Elena A. Smolyarchuk, Victor A. Manuylov, Daria V. Vasina, Vladimir A. Gushchin, and Alexander L. Gintsburg. 2020. "Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study" Vaccines 8, no. 4: 652. https://doi.org/10.3390/vaccines8040652